Sort
23,748 grants matching “melanoma”
In-situ activation of antitumor effectors
$304,071Edmund C. Lattime · Univ Of Med/Dent Nj-R W Johnson Med Sch · R01 · FY2006 · CA
CORE--INFORMATICS, TISSUE RESOURCE, AND PATHOLOGY
$304,025Jeffrey E Gershenwald · University Of Tx Md Anderson Can Ctr · P50 · FY2008 · CA
Structure and function of novel G protein conformations
$304,002Sharon L Campbell · Univ Of North Carolina Chapel Hill · R01 · FY2017 · GM
Structure and function of novel G protein conformations
$304,002Sharon L Campbell · Univ Of North Carolina Chapel Hill · R01 · FY2016 · GM
PROLIFERATIVE CONDITIONING OF TUMOR-COMPETENT DENDRITIC CELL PRECURSORS
$304,000Peter A Cohen · Mayo Clinic Arizona · R01 · FY2010 · CA
PROLIFERATIVE CONDITIONING OF TUMOR-COMPETENT DENDRITIC CELL PRECURSORS
$304,000Peter A Cohen · Mayo Clinic Arizona · R01 · FY2009 · CA
TCR Affinity and Therapeutic Efficacy of T Cells
$303,994Michael I Nishimura · Medical University Of South Carolina · R01 · FY2007 · CA
Mechanisms of Immune-mediated Tumor Cell Destruction
$303,991Thomas Sayers · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA
Inhibiting Multiple Molecular Targets for Preventing Non-Melanoma Skin Cancer
$303,988Mohammad Athar · University Of Alabama At Birmingham · R01 · FY2011 · CA
Myxoma Virus (MV) Oncolysis for treating human cancer
$303,988Grant McFadden · University Of Florida · R01 · FY2010 · CA
Inhibiting Multiple Molecular Targets for Preventing Non-Melanoma Skin Cancer
$303,988Mohammad Athar · University Of Alabama At Birmingham · R01 · FY2015 · CA
Inhibiting Multiple Molecular Targets for Preventing Non-Melanoma Skin Cancer
$303,988Mohammad Athar · University Of Alabama At Birmingham · R01 · FY2012 · CA
The Role of HEF1 in Ovarian Cancer Development, Progression, and Metastasis
$303,948Denise C Connolly · Research Inst Of Fox Chase Can Ctr · R01 · FY2013 · CA
Akt3 Signaling as a Therapeutic Target
$303,925Gavin P. Robertson · Pennsylvania State Univ Hershey Med Ctr · R01 · FY2012 · CA
Akt3 Signaling as a Therapeutic Target
$303,925Gavin P. Robertson · Pennsylvania State Univ Hershey Med Ctr · R01 · FY2011 · CA
Project 3: Prognostic and Functional Role of a Gene Expression Signature in Melanoma Patients
$303,874Eva Hernando · University Of New Mexico Health Scis Ctr · P01 · FY2017 · CA
Synergy of the innate and acquired immune responses in tumor immunology
$303,810Randolph J. Noelle · Dartmouth College · R01 · FY2009 · CA
Synergy of the innate and acquired immune responses in tumor immunology
$303,810Randolph J. Noelle · Dartmouth College · R01 · FY2007 · CA
Synergy of the innate and acquired immune responses in tumor immunology
$303,810Randolph J. Noelle · Dartmouth College · R01 · FY2010 · CA
Synergy of the innate and acquired immune responses in tumor immunology
$303,810Randolph J. Noelle · Dartmouth College · R01 · FY2008 · CA
New Target Antigens for Prostate Cancer Immunotherapy
$303,809Vaccinex, Inc. · R43 · FY2004 · CA
Targeted Molecular Therapeutics for Melanoma: CCI-779 and Bevacizumab
$303,751Craig Lee Slingluff · University Of Virginia · R21 · FY2007 · CA
MELANOMA ASSOCIATED T AND DC DYSFUNCTION AND DEATH
$303,750University Of Pittsburgh At Pittsburgh · R01 · FY2001 · CA
Core 3-Biostatistics
$303,698J. Jack Lee · University Of Tx Md Anderson Can Ctr · P50 · FY2023 · CA
Skin Cancer Chemoprevention by Silibinin: Mechanisms and Efficacy
$303,684Rajesh Agarwal · University Of Colorado Denver · R01 · FY2012 · CA